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26 The use of geo-engineering materials to manage phosphorus in lakes has increased in recent years 
27 with aluminium and lanthanum based materials being most commonly applied. Hence the potential 
28 impact of the use of these compounds on human health is receiving growing interest. This review 
29 seeks to understand, evaluate and compare potential unintended consequences on human health and 
30 ecotoxicological risks associated with the use of lanthanum- and aluminium-based materials to modify 
31 chemical and ecological conditions in water bodies. In addition to their therapeutic use for the 
32 reduction of intestinal phosphate absorption in patients with impaired renal function, the phosphate 
33 binding capacity of aluminium and lanthanum also led to the development of materials used for water 
34 treatment. Although lanthanum and aluminium share physicochemical similarities and have many 
35 common applications, their uptake and kinetics within the human body and living organisms 
36 importantly differ from each other which is reflected in a different toxicity profile. Whilst a causal role in 
37 the development of neurological pathologies, skeletal lesions, hematopoietic disorders and respiratory 
38 effects has unequivocally been demonstrated with increased exposure to aluminium, studies until now 
39 have failed to find such a clear association after exposure to lanthanum although caution is warranted.  
40 Our review indicates that lanthanum and aluminium have a distinctly different profile with respect to 
41 their potential effects on human health. Regular monitoring of both aluminium and lanthanum 
42 concentrations in lanthanum-/aluminium-treated water by the responsible authorities is recommended 
43 to avoid acute accidental or chronic low level accumulation. 
44
45 Highlights
46  Geo-engineering materials containing La and Al used to manage P in lakes
47  Potential impact of the use of these compounds on human health is of interest
48  La and Al uptake, kinetics and toxicity profile differ within the humans and organisms
49  Monitoring of La and Al is recommended to avoid acute and chronic exposure.
50
51 Keywords





55 Aluminium is a ubiquitous substance encountered both naturally (as the third most abundant element) 
56 and intentionally (used in water treatment, foods, pharmaceuticals, and vaccines); it is also present in 
57 ambient and occupational airborne particulates. Existing data underscore the importance of the 
58 physicochemical characteristics of aluminium in relation to its uptake, accumulation, and systemic 
59 bioavailability (Van Landeghem et al. 1997; Willhite et al. 2014). Aluminium has been shown to have 
60 the potential to be a toxicant to the central nervous, skeletal and hematopoietic systems. This is most 
61 prevalent through exposure to aluminium-contaminated dialysis and intravenous fluids and oral 
62 consumption of large amounts of aluminium-containing antacids and phosphate binders, especially in 
63 patients with impaired renal function. Although caricatural aluminium overload, reflected by blood and 
64 tissue levels being up to 1000 times higher compared to those currently observed has now 
65 disappeared, data in the literature suggest that low level exposure to aluminium via drinking water in 
66 individuals with normal renal function may be a contributing factor in the development of Alzheimer’s 
67 disease and related disorders (Yokel and McNamara 2000, Bondy 2016). With regard to drinking 
68 water exposure, an important question is whether the aluminium is derived from natural sources for 
69 instance from ingestion of clay minerals (geophagia) or as a consequence of water treatment 
70 methods. Water treatment using aluminium sulphate, i.e. alum, generally increases the percentage of 
71 dissolved, low molecular weight, (poly) aluminium species that are chemically reactive and possibly 
72 more readily absorbed, especially when used in lakes with low to moderate alkalinity (Cooke et al. 
73 1993; Stevenson and Vance 1989; Yokel and McNamara, 2000).   
74 In comparison to aluminium, the ubiquity of lanthanum in the environment as well as the element’s 
75 industrial applications and use in daily life is significantly less. As compared to aluminium there is less 
76 evidence for lanthanum toxicity through environmental and medical exposure which is mainly due to 
77 differences in gastrointestinal absorption, uptake kinetics, tissue accumulation and routes of 
78 elimination. Importantly, however, that with exception of its therapeutic use of lanthanum in uremic 
79 patients, much less experimental and epidemiological studies have been performed so far that have 
80 evaluated the potential toxicity of long-term low level environmental exposure. With the relatively 
81 recent introduction of the lanthanum-modified bentonite (LMB), commercially known as Phoslock 
82 (Douglas 2002; Douglas et al. 2004, 2008; Robb et al. 2003) for use in phosphorus management in 
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83 polluted freshwaters, an assessment of the potential effects of lanthanum on human health deserves 
84 increasing attention.       
85 The use of geo-engineering materials to control phosphorus in lakes has increased in recent years 
86 with aluminium and lanthanum based materials being most commonly applied (Copetti et al. 2016; 
87 Huser et al. 2016). Given that these materials are used to achieve improvements in chemical and 
88 ecological conditions in water bodies it is understandable that efforts to forecast potential unintended 
89 consequences have focused on ecotoxicological risks associated with aluminium (Reitzel et al. 2013) 
90 and lanthanum (Spears et al. 2013). However, as these materials are frequently used to control 
91 harmful algal blooms in recreational water bodies (Lürling and van Oosterhout 2013; Lurling and 
92 Tolman 2010; Meis et al. 2012), direct contact with treated waters by humans is unavoidable. For 
93 example, LMB was used as a preventative measure in both Strathclyde Loch and The Serpentine 
94 during the Commonwealth Games (Glasgow, 2014), and Olympic Games (London, 2012), 
95 respectively, to reduce the risk of human health effects associated with cyanobacteria during open 
96 water swimming events. In addition, the use of geo-engineering materials in drinking water reservoirs 
97 has received attention given the potential for mass human exposure through drinking water supplies 
98 (Perkins and Underwood 2001; Schintu et al. 2000). Assessments of the risk posed by human 
99 consumption of fish in treated waters have also been conducted (Landman and Ling 2006; Landman 
100 et al. 2007). In recognition of these concerns, the use of LMB has been assessed in the context of 
101 human and environmental health protection and associated legislative mechanisms (NICNAS, 2014).    
102 To aid water managers in the selection and appropriate use of geo-engineering materials it is 
103 important to comprehensively assess the potential for heightened human health risks across a wide 
104 range of water body types. To address this, we review here the occurrence, metabolism, routes of 
105 exposure, and potential toxicity associated with water bodies treated with lanthanum and aluminium, 
106 two of the most commonly used materials for phosphorus control (Lürling et al. 2016). We draw on 
107 evidence of concentrations of chemical species reported for treated water bodies and provide 
108 recommendations for use of materials in the context of dose and effect scenarios. The assessment 
109 approach used here has relevance for the comparative assessment of other materials proposed for 




112 Occurrence and exposure of lanthanum
113 Lanthanum, a member of the element group called rare earth elements (REE) or lanthanides, is 
114 relatively common in the earth's crust. Its abundance may be as high as 18 parts per million (Redling 
115 2006), making it nearly as common as copper or zinc. Lanthanum is widely dispersed throughout the 
116 earth's crust, most commonly occurring in REE minerals such as monazite and bastnasite. These 
117 minerals generally contain all of the other REE, often in variable abundance. Reports on 
118 environmental pollution by lanthanum are scarce and mainly originate from particular regions in China 
119 (Zhao et al. 2013).  The element, lanthanum, is increasingly used in industrial applications with some 
120 of its compounds being used in lamps, color televisions, cigarette lighters, optical fibers and hybrid 
121 engines (Behets 2005; Das et al. 1988). According to a recent survey, the annual production of 
122 lanthanum was 12,500 tonnes worldwide (Hague et al., 2014). Plants generally do not accumulate 
123 lanthanum, although in some instances, accumulation of REE has been described for tea, cucumber, 
124 maize and pine leaves (Xu et al. 2003). Mosses and lichen generally contain the highest lanthanum 
125 concentrations (up to 100 ppm) (Behets 2005, Das et al. 1988; Xu et al. 2012). 
126 Occurrence and exposure of aluminium
127 Aluminium (Al) is the most abundant metallic element within the lithosphere, occurring at about 8% by 
128 weight (so over 4000 times more enriched relative to lanthanum) and the third most abundant element 
129 preceding iron (4.7%) but less abundant than oxygen and silicon. Aluminium exists primarily 
130 associated with silicates and oxides in minerals of low solubility, explaining the low (generally <1 mg/L) 
131 dissolved aluminium concentrations detected in rivers, lakes and sea water (Gensemer and Playle 
132 1999). Nevertheless, reports in the early 1980s pointed towards acidification of lakes as a result of 
133 acid rain thereby enhancing aluminium solubility below pH 6 and hence toxicity for fish and other biota 
134 including birds living in the immediate surroundings (Van Landeghem 1997). 
135 Today the daily ingested dose via drinking water is estimated to be around 160 µg aluminium/day 
136 (Willhite et al. 2014). Thanks to governmental efforts to reduce the release of sulphur dioxide (SO2) 
137 into the atmosphere emissions in the US and Europe dropped 40% and 70% respectively since the 
138 1990s whilst according to the Pacific Research Institute, acid rain levels have dropped 65% since 
139 1976 (http://en.wikipedia.org/wiki/Acid_rain). Human activities have also changed exposure of living 
140 organisms to aluminium in other ways since it is widely used in transportation, packaging, 
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141 construction, water treatment, a wide range of household items (Frumkin et al. 2008). In 2014 the 
142 global annual aluminium production had reached 54 million tons. It has been reported that exposure to 
143 aluminium may also occur through aluminium leaching from ceramic products (Bolle et al. 2011), 
144 migration from glass bottles (Fekete et al. 2012), smoking (Exley and Begum 2006a), in some 
145 antacids, and prescription phosphate binders. Hence, it is not surprising that depending on location, 
146 weather conditions, and type and level of industrial activity in the area, daily exposures may range 
147 from 0.005-0.18 µg/m3 in clean ambient air to 0.4-8.0 µg/m3 in urban and industrial areas. Hence 
148 exposure rates may be as little as 0.03 µg/kg/day (assuming a 70 kg body weight) in clean air to 233 
149 µg/kg/day in polluted air to as high as 3500-5200 mg aluminium/day (i.e. 50 mg/kg/day-75 mg/kg/day) 
150 as a result of aluminium-based antacid consumption (D’Haese 1988; Krewski et al. 2007; 
151 https://www.atsdr.cdc.gov/phs/phs.asp?id=1076&tid=34). To appreciate health consequences of 
152 aluminium exposure it is important to consider that the speciation is more influential to health 
153 outcomes than exposure per se (Willhite et al. 2014), which is also applicable to other elements, 
154 including lanthanum.
155 Aqueous chemistry of lanthanum 
156 Lanthanum (La), electron configuration (Xe) 5d1 6s2, atomic mass 138.91, is the most electropositive 
157 (cationic) element of the REE, is uniformly trivalent and its binding is generally ionic. It is a so-called 
158 hard electron acceptor with a strong preference for oxygen-containing anions. Therefore, the most 
159 common biological ligands with which it can form strong complexes are carboxyl and phosphate 
160 groups. Carbonates, phosphates and oxalates formed with lanthanum are essentially insoluble, while 
161 the chloride and sulphate complexes are soluble (Cetiner et al. 2005; Cetiner and Xiong 2008). In 
162 aqueous solutions without any other oxyanions present, chemical modelling indicates that the majority 
163 of lanthanum occurs as a free La3+ cation until pH8 (Figure 1).  Above this pH a series of La-OH 
164 complexes coexist with the insoluble La(OH)3 complex predominating between approximately pH9 and 
165 pH12. In lake restoration, lanthanum is used to intercept phosphate released from sediments and to 
166 reduce water column phosphate. Lanthanum and phosphate bind to rhabdophane (LaPO4), a mineral 
167 with an extreme low solubility (Ksp 10-24.7 to 10-25.7 mol2 l-2) (Johannesson and Lyons 1994, Liu and 
168 Byrne 1997). The lanthanum-phosphate bond is only affected by conditions where pH is <4 or >12. 
169 The phosphate binding capacity of lanthanum is not affected by altered redox conditions such as 
170 those in anoxic waters (Ross et al. 2008). The formation of rhabdophane is not only predicted by 
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171 chemical equilibrium modelling, but also has been found in sediments of 10 treated lakes across 
172 Europe (Dithmer et al. 2016). Given that rhabdophane is extremely stable and will not “separate”, the 
173 equilibrium is de facto a precipitation reaction. Consequently, any phosphate bound to lanthanum can 
174 be viewed as permanently removed from the biogeochemical cycling. An example of this is the 
175 persistence of LaPO4 minerals in the weathering cycle that may span millions of years.  
176 Aqueous chemistry of aluminium 
177 Aluminium (Al), electron configuration (Ne) 3s2 3p1, molecular mass 26.98, exists exclusively in the 
178 trivalent oxidation state. It is amphoteric, combining with both acids and bases to form, respectively, 
179 aluminium salts and aluminates. As it combines a relatively small ionic radius (0.54 Å) with a high 
180 charge the free Al3+ concentration in aqueous solutions is very low due to the formation of aluminium 
181 hydroxide complexes. The chemical nature of aluminium in water is essentially the chemistry of 
182 Al(OH)3 which has an amphoteric character and a tendency to form complex ions and to polymerize. 
183 Evidence has been provided by chemical modelling that in solutions with a pH below 5, aluminium 
184 exists predominantly as Al(H2O)63+, with rising pH an insoluble Al(OH)3 complex forms at circumneutral 
185 pH, which re-dissolves at higher pH as the Al(OH)4- (aluminate) complex (Figure 1) (Anderson and 
186 Berkowitz 2010; Gensemer and Playle 1999; Reitzel et al. 2013). Importantly, the speciation of 
187 aluminium is remarkably similar to that of lanthanum, albeit with the majority of similar Al-OH species 
188 offset by 4-5 pH units lower (Figure 1). In lake restoration, aluminium is used as a coagulant to settle 
189 particulate matter, to complex with water column and sediment released phosphate (Cooke et al. 
190 1993). The chemistry of aluminium is complex, as hydrolysis of aluminum is pH and temperature 
191 dependent, and amorphous aluminium hydroxide, bayerite, gibbsite with attached phosphates may 
192 form. These forms may either loose some of the attached phosphates or loose binding capacity 
193 because (i) Al(OH)3 begins to crystallize after forming (Berkowitz et al. 2006; de Vincente et al. 2008), 
194 (ii) are stable over a smaller pH range compared to LaPO4, but are just like lanthanum in that they are 
195 redox insensitive. Under high phosphate conditions minerals such as variscite (AlPO4·2H2O) and 
196 kingite (Al3(PO4)2(OH)3·9H2O) may be formed. 
197 Metabolism 
198 Inhalation of lanthanum. 
ACCEPTED MANUSCRIPT
6
199 Lanthanum in combination with other REE may accumulate in the lungs after inhalation, mainly in 
200 occupational settings. Taking into account the limited pathological potential of REE for pulmonary 
201 lesions in combination with modern occupational exposure practices which efficiently restrict the 
202 respiratory intake of particles at work sites, health impairment is not readily expected (Redling 2006; 
203 Richter 2003). Electron microscopic evidence for cerium and lanthanum particles in the lung was 
204 provided in a single patient with an occupational history of REE exposure and affected by dendriform 
205 pulmonary ossification and pneumoconiosis (Yoon et al. 2005).  
206 Inhalation of aluminium 
207 Aluminium workers can encounter a mixture of aluminium fumes and inhalable (aerodynamic diameter 
208 <100µm), thoracic (<28µm), and respirable (<10µm) aluminium particles in the occupational 
209 environment (Willhite et al. 2014). A fraction of the aluminium present in dust remains indefinitely in 
210 the lungs after inhalation, thus without entering systemic blood circulation. Hence, unlike other tissue 
211 stores of aluminium, concentrations in the lung increase with age (Han et al. 2004).
212 Ingestion and gastrointestinal absorption of lanthanum 
213 Lanthanum, as all lanthanide elements, forms soluble chlorides and nitrates, but their phosphates and 
214 carbonates are generally insoluble and therefore have a low potential for systemic absorption. Studies 
215 have shown that oral doses of lanthanum are only minimally absorbed from the gut. When given as 
216 lanthanum carbonate to rats, the oral bioavailability was 0.0007% (Damment and Pennick 2007) whilst 
217 in humans the average systemic bioavailability across different studies was 0.00089 ± 0.00084% 
218 (n=25) with the highest bioavailability in any subject being 0.00294%. No clear differences in 
219 bioavailability were seen between healthy volunteers and dialysis patients, i.e. the target population for 
220 phosphate binding treatment with lanthanum carbonate (Damment and Pennick 2008; Pennick et al. 
221 2006;).
222 Ingestion and gastrointestinal absorption of aluminium
223 Daily intake of aluminium from food is considered small. Recent studies suggest that it is in the range 
224 of 2-5mg/day (Crisponi et al. 2013). The gastrointestinal absorption of aluminium is profoundly affected 
225 by speciation (e.g. aluminium citrate versus aluminium hydroxide) and reported fractional 
226 gastrointestinal absorption varies between 0.001% and 27% (Drüeke 2002). The main reasons for this 
227 lack of agreement are related to analytical detection, contamination and differences in experimental 
ACCEPTED MANUSCRIPT
7
228 protocols. With the introduction of  accelerator mass spectrometry (AMS) and the possibility of using 
229 the 26Al radioisotope more reliable data were generated, which however, still varied between 0.04% 
230 and 1.0% (Jouhanneau et al. 1993). A fractional gastrointestinal absorption of ± 0.2% is now generally 
231 accepted (Shirley and Lote 2005). It is believed that intestinal absorption of aluminium includes both (i) 
232 paracellular pathways along enterocytes and through tight junctions by passive processes and, (ii) 
233 transcellular pathways through enterocytes involving both active and passive processes. Other factors 
234 that have been reported to alter intestinal aluminium absorption include calcium, iron status, 
235 parathyroid hormone, vitamin D, and the uremic state (Van Landeghem et al. 1997).    
236 Lanthanum in blood/plasma
237 Background concentrations in chronic renal failure patients not treated with lanthanum carbonate 
238 revealed concentrations of <0.05 to 0.90 µg/L in plasma whilst in subjects with normal renal function 
239 values consistently are below 0.05 µg/L (Pennick et al. 2006). In vitro binding studies demonstrated 
240 that lanthanum is extensively bound (>99.7%) to plasma proteins (Damment and Pennick 2007). In 
241 dialysis patients (N=93) treated with lanthanum carbonate on a daily basis over six years, plasma 
242 lanthanum concentrations > 2.0 µg/L were recorded in only 15 out of a total of 574 analyses with no 
243 evidence of safety concerns or increased frequency of adverse events (Hutchison et al. 2008).  
244 Aluminium in serum/plasma
245 Serum aluminium concentrations in healthy non-exposed subjects as measured using appropriate 
246 contamination free techniques are below 2.0 µg/L and should not exceed 10 µg/L. (Guidelines for 
247 aluminum toxicity are mainly based on the toxic effects seen in patients with impaired renal function. In 
248 these patients a serum aluminum level (D’Haese and De Broe, 2007):    
249 < 30 µg/L: aluminum-related bone disease is unlikely but possible particularly when patients are iron-
250 overloaded
251 30-60 µg/L: aluminum-related bone disease is quite possible, especially if serum parathyroid hormone 
252 (PTH) levels are low or low-normal
253 > 60 µg/L: aluminum-related bone disease is probable, but not invariably present, especially if serum 
254 PTH levels are high, iron-transferrin saturation is low.
255 > 100 µg/L: aluminum-related bone disease is most probable unless patients are iron deficient. 
256 Neurologic disorders should be checked for by taking the patients’ electroencephalogram. 
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257 Whilst in the past values up to >500 µg/L were seen in uremic patients treated with aluminium-
258 containing phosphate binders either in combination with aluminium-contaminated dialysis fluids or not, 
259 nowadays with the introduction of aluminium-free medication and high performance water treatment 
260 systems concentrations above 10 µg/L are rarely seen. The majority (80-90%) of aluminium in serum 
261 is bound to transferrin which can accommodate two aluminium ions, the first at the C-lobe and the 
262 second at the N-lobe (Mujika et al. 2012), and is considered the most important, if not the sole, carrier 
263 protein of the element in plasma (Van Landeghem et al. 1994, 1998) with the remainder fraction 
264 bound to low molecular mass compounds. Hence, it is not surprising that the protein bound fraction is 
265 influenced by the iron status; i.e. iron-transferrin saturation, as both elements compete for binding to 
266 transferrin (Van Landeghem et al. 1997). This implies that when iron-transferrin saturation is high there 
267 is less binding of aluminium to transferrin, hence, more non-protein bound aluminium, i.e. free 
268 aluminium in circulation which thus becomes available (i) for being deposited in the calcified bone 
269 compartment thereby impairing bone mineralisation, (ii) to pass the blood brain barrier by which it may 
270 induce deleterious neurological effects. On the other hand when iron transferring saturation is low, 
271 more aluminium will bind to transferrin which however may be taken up by the parathyroid gland 
272 through transferrin-mediated endocytosis which in turn may lead to a decreased PTH 
273 secretion/synthesis, hence hypoparathyroidism ensuing in the so-called adymamic or low turn-over 
274 bone disease (D’Haese1988; Smans et al., 2000; Van Landeghem et al., 1997 & 1998a). 
275 Once bound to transferrin, studies from Mujika et al. (2012) revealed that conformational changes 
276 under conditions where Tyr188 is protonated permit aluminium release from the protein.  
277 Tissue distribution of lanthanum 
278 Data on the tissue distribution in humans, with the exception of lanthanum concentrations measured in 
279 the framework of clinical studies evaluating the therapeutic use of lanthanum carbonate, are scarce. 
280 Studies in animals with normal renal function and chronic renal failure that were environmentally 
281 exposed revealed that lanthanum concentrations in various tissues did not exceed 0.08 µg/g wet 
282 weight and this was not dependent on renal function. In rats treated with lanthanum carbonate at an 
283 oral dose of 2000 mg/kg/day over a 12 week exposure, a substantial increase was seen, particularly in 
284 bone, liver and kidney with liver lanthanum concentrations in uremic rats being 2- to 3-fold higher than 
285 those seen in non-uremic rats (Slatopolsky et al. 2005). This may be ascribed to a disruption of the 
286 intercellular junctions in the intestinal epithelium inherent to chronic renal failure. A carefully controlled 
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287 time-course rat study, however, showed that steady-state concentrations of about 3 µg/g wet weight 
288 were achieved within 6-12 weeks of treatment, indicating hepatic lanthanum uptake and elimination to 
289 be in equilibrium (Bervoets et al. 2009). Lanthanum concentrations in bone biopsy samples of patients 
290 being treated with pharmacological doses of lanthanum carbonate during 12 months revealed 
291 concentrations of 1.8 µg/g wet weight (D’Haese et al. 2003) whilst in patients treated for 4-5 years the 
292 average measured bone lanthanum concentration was 5 µg/g wet weight (unpublished data).  
293 Tissue distribution of aluminium 
294 In adults with normal renal function the total aluminium burden is estimated to be 30 mg with the 
295 highest concentrations found in the lungs, skeleton and skeletal muscles. Chronic accumulation 
296 occurs in patients with end-stage renal disease because the major elimination route; i.e. the kidney, 
297 does not function. In these patients a somewhat different distribution pattern is seen particularly in 
298 those taking aluminium-containing medication or being treated with aluminium-contaminated dialysis 
299 fluids. In these patients highest concentrations were observed in the liver, bone (up to 200 µg/g wet 
300 weight), spleen and parathyroid glands (D’Haese 1988; D’Haese et al. 1999, 1999a). Tissue 
301 distribution/elimination further depends on the element’s concentration and speciation (van Ginkel et 
302 al. 1993). Data from various studies indeed point toward a preferential transport of the circulating 
303 aluminium-transferrin complex to tissues expressing transferrin receptors such as the liver and the 
304 spleen. However, aluminium bound to citrate (or low molecular mass components in general) will in 
305 the presence of an intact renal function rapidly be excreted whereas in the absence of a renal function 
306 low molecular mass Al compounds will by preference be deposited at the bone mineralization surface, 
307 an area with no transferrin receptors (Van Landeghem et al. 1998). 
308 Elimination of lanthanum  
309 The kidneys are responsible for eliminating only a very small fraction of systemic lanthanum which 
310 also explains the lack of appreciable plasma lanthanum concentrations over time in uremic patients. 
311 Following intravenous administration of lanthanum chloride to rats, biliary excretion was the 
312 predominant route of elimination, with 85.6% of recovered lanthanum collected from bile over a period 
313 of 5 days. Experimental studies presented evidence for lanthanum to be transported and eliminated by 




316 Elimination of aluminium
317 Although only a small fraction of ingested aluminium is absorbed, and thus enters the blood 
318 compartment, it is vital that absorbed aluminium is quickly removed from the body because aluminium 
319 accumulation is a risk factor in a number of disorders (see below). A small amount of aluminium is 
320 excreted in the bile, but the major route of aluminium elimination is via the kidney. Hence it is not 
321 surprising that most healthy adults can tolerate large repeated daily oral aluminium exposure (up to 
322 3500 to 7200 mg/day from e.g. antacids or buffered aspirin) without any adverse effect but that other 
323 people; i.e. preterm infants, young children and in particular patients with impaired renal function are at 
324 serious risk of aluminium accumulation/toxicity at even much lower daily doses (Willhite et al. 2014). In 
325 vitro determinations using artificial membranes indicated that ±10% of the total amount of circulating 
326 aluminium is filtered at normal plasma concentrations which is similar to the unbound aluminium 
327 fraction. However, when plasma aluminium is raised experimentally, its filterability falls, unless the 
328 excess aluminium is complexed with citrate whereby the aluminium citrate complex appears to be 
329 freely filtered. Information on tubular reabsorption of aluminium at normal plasma concentrations is 
330 inconsistent. Filtered aluminium appears to be at least partially reabsorbed, although the reabsorptive 
331 mechanisms remain speculative. A consensus is emerging that elevated plasma aluminium 
332 concentrations result in a fall in fractional aluminium reabsorption, and a recent micropuncture study 
333 indicates that under these circumstances the only significant site of aluminium reabsorption is the loop 
334 of Henle (Shirley and Lote, 2005).
335 General toxicity
336 Lanthanum 
337 Although lanthanum has no known biological role, with the REE including lanthanum generally 
338 considered to be of low toxicity, and depending on its chemical form, the acute oral dose of lanthanum 
339 as assessed in rats varies from 3400 mg/kg body weight (lanthanum-ammonium nitrate) to > 10000 
340 mg/kg body weight (as lanthanum oxide) (Redling, 2006). Evaluation of potential genotoxicity using a 
341 range of in vitro assays in the presence and absence of post-mitochondrial fraction (S9) and in vivo in 
342 three independent tests for mutagenicity and clastogenicity indicated that lanthanum is not genotoxic 
343 and that lanthanum carbonate is unlikely to present a latent hazard in therapeutic use (Damment et al., 
344 2005). A single experimental study in mice reported nephrotoxic effects associated with oxidative 
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345 stress through exposure to lanthanides. The most severe damage was induced by epigastric exposure 
346 to cerium chloride followed by neodymium chloride whilst only minor damage was seen with 
347 lanthanum chloride (Zhao et al. 2013). Results from another experimental study in mice suggested 
348 that these lanthanides enter hepatocytes and mainly accumulate in the nuclei and induce oxidative 
349 damage in hepatic nuclei and mitochondria (Huang et al. 2011). To what extent these observations 
350 are clinically relevant needs to be determined. Hormetic concentration-related trends, implying 
351 stimulatory or protective effects at low levels, then adverse effects at higher concentrations have been 
352 reported for lanthanum in various models including seedings, bovine vascular smooth muscle cells 
353 and murine preosteoblast cells (Pagano et al. 2015).      
354 Aluminium 
355 Despite the ubiquity of aluminium in the environment and its presence in living organisms, albeit in 
356 small concentrations (ppb-ppm range), no biological function has so far been attributed. For this 
357 reason aluminium is considered to be a nonessential metal. Aluminium has long been considered inert 
358 for living organisms and as such was not regarded as a toxic element until the 1960s. At that time only 
359 a few reports dealt with the toxic effects of aluminium in humans and animals, which, however, did not 
360 receive much attention (Van Landeghem et al. 1998). In the 1970s, the element was linked to 
361 particular disease states noticed in patients with end-stage renal failure particularly those treated by 
362 dialysis (Alfrey et al. 1972, 1976; Berlyne et al. 1970). Although aluminium toxicity is mainly a matter of 
363 concern in dialysis patients and the element is adequately removed by the kidneys, occupationally 
364 exposed workers (e.g., welders) are also at risk for the deleterious effects of aluminium. In the latter 
365 population growing evidence is being provided for the element to cause pulmonary lesions (Kongerud 
366 et al. 2014; Raghu et al. 2014) as well as neurological disorders (Sińczuk-Walczak et al. 2003). 
367 Because of its persistence in the environment and the frequency of exposure of the general 
368 population, intensive research was been conducted during the last decades to unravel the 
369 mechanism(s) underlying the element’s potential health effects. Owing to its physicochemical 
370 characteristics aluminium has been reported to perturb iron homeostasis, disrupt biological 
371 membranes, enhance reactive oxygen species, and damage DNA (Exley, 2004; Exley, 2006b; Kumar 
372 et al. 2009; Mailloux et al. 2011; Zatta et al. 2002). Exposure of neurons and astrocytes to aluminium 
373 is known to activate apoptotic cascades, provoke cell cycle arrest, and interfere with cell signaling 
374 pathways (Drago et al. 2008; Lemire et al. 2009). Hence it is not surprising that during the last decade 
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375 much attention has been paid to the potential neurotoxic effects of aluminium in humans and 
376 numerous groups assessed the aluminium content in the brain of subjects with various neurological 
377 disorders, in particular those with Alzheimer disease as well as non-affected individuals. Most of these 
378 data have been summarized by Exley and House (2011) reporting a normal range between 0.1 and 
379 4.5 µg/g dry weight with the higher values (>2 µg/g dry weight) in brains of non-demented elderly, 
380 Alzheimer patients (up to 11.5 µg/g dry weight), dialysis encephalopathy (up to 14.1 µg/g dry weight – 
381 see below also), congophilic amyloid angiopathy (up to 23.0 µg/g dry weight) and other 
382 encephalopathies (up to 47.4 µg/g dry weight). Despite these numerous data the question as to 
383 whether in the general population, aluminium exposure is either the cause, a potential contributor to 
384 the onset, progression and aggressiveness, or increased concentrations in the brain are the 
385 consequence of the neurological condition itself, with exception to dialysis encephalopathy, has been 
386 a matter of debate for many years (Kawahara et al. 2011; Martyn et al. 1989; Willhite et al. 2014). 
387 Therapeutic use 
388 Lanthanum
389 Because of its low solubility, lanthanum carbonate was preferred to lanthanum chloride for further 
390 investigation on its therapeutic use as an intestinal phosphate binder. In the acidic environment of the 
391 stomach and upper small intestine, lanthanum dissociates sufficiently to become available for 
392 phosphate binding. In vitro more than 97% of phosphate was removed by a two-fold molar excess of 
393 lanthanum carbonate (Autissier et al. 2007). In vivo in a rat model with chronic renal failure, lanthanum 
394 carbonate was as effective as aluminium hydroxide and more effective than calcium carbonate or 
395 sevelamer (a polymeric amine that binds phosphate) at binding dietary phosphate at equivalent doses 
396 (Damment 2011). In contrast to concurrent phosphate binding agents intestinal phosphate binding of 
397 lanthanum carbonate does not depend on variations in intestinal pH (Autissier et al. 2007). As biliary 
398 excretion is the major route of elimination of lanthanum and gastrointestinal absorption of the element 
399 is minimal, its therapeutic use in individuals with a compromised renal function does not expose them 
400 to an increased risk of systemic accumulation as compared to subjects with normal renal function. 
401 Long-term experimental studies in which rats with either chronic renal failure or normal renal function 
402 were administered lanthanum carbonate by oral gavage on a daily base at doses up to 2000 mg/kg 
403 (corresponding to a daily dose of 150g/day in humans) did not show significant direct adverse effects 
404 on bone (Behets et al. 2005a, 2005b; Bervoets et al. 2006). In contrast to aluminium (see below), in 
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405 bone, lanthanum could be localized at sites of active as well as non-active bone 
406 remodeling/mineralization with no association between histological deposition sites and the typical 
407 bone pathologies observed in renal failure (Behets et al. 2005c). As mentioned above, in the liver the 
408 localization of the element is lysosomal whilst lanthanum treatment during 20 weeks at a daily 1000 
409 mg/kg/day dose was not accompanied by an increased concentration of liver enzymes (Yang et al. 
410 2006; Bervoets et al. 2009). Following gavage (863 mg/kg/day during several weeks) or intravenous (a 
411 route enabling >300-fold higher plasma lanthanum concentrations) administration (0.03 mg/kg/day) of 
412 lanthanum, median brain concentrations remained near the lower limit of quantification (2.4 ng/g). This 
413 together with data from ultrastructural studies thus provide strong evidence that lanthanum does not 
414 cross the blood-brain barrier (Damment et al. 2009). In patients, lanthanum carbonate monotherapy 
415 was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased 
416 frequency of adverse events (Hutchison et al. 2008). A 2-year follow up study in hemodialysis patients 
417 indicated that lanthanum carbonate as a phosphate binder did not adversely affect cognitive function 
418 compared with standard therapy (Altmann et al. 2007) whilst a bone-biopsy based study in dialysis 
419 patients receiving a median daily dose of 1250 mg elemental lanthanum/day showed an evolution 
420 towards normal bone histology and absence of aluminium-like effects (see below) on bone after 1-year 
421 treatment (D’Haese et al., 2003). 
422 Aluminium
423 Being widely used in the past, aluminium hydroxide has proven to be a highly effective phosphate 
424 binder. Its substantial gastrointestinal absorption and renal route of elimination however posed its 
425 target population for therapeutic use to an increased risk of accumulation. In the past aluminium-
426 phosphate binder treatment, in particular when used in combination with aluminium-contaminated 
427 dialysis fluids (see below) led to the development of severe side-effects, mainly in the bone and brain. 
428 In bone, aluminium accumulates at the osteoid calcification front, a critical site of bone mineralization 
429 which at high exposure leads to the so-called aluminium-induced osteomalacia, a disease manifested 
430 by recurrent fractures and resistance to vitamin D therapy (Goodman 1985; Verbueken et al. 1984). 
431 This type of bone disease is characterized by an increased amount of osteoid due to a defective 
432 mineralization. Another type of aluminium-related bone disease is adynamic bone characterized by a 
433 dramatically reduced bone turn-over, and absence of osteoblasts, osteoclasts and osteoid (Goodman 
434 1985). Aluminium is unquestionably neurotoxic in patients treated by dialysis. The so-called dialysis 
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435 encephalopathy syndrome, the result of acute intoxication of aluminium caused by the use of an 
436 aluminium-containing dialysate, was a common occurrence prior to 1980 (Rob et al. 2001; Ward et al. 
437 1978). Although with the introduction of modern techniques of water purification, acute intoxication can 
438 now be avoided, occurrences of aluminium intoxication may still occur (D’Haese and De Broe, 1996; 
439 Simoes et al., 1994;), and chronic moderately elevated concentrations may still be seen in dialysis 
440 centres in particular regions (Hou et al. 2010). The neurologic symptoms may be precipitated by 
441 concomitant ingestion of aluminium-containing phosphorus binders and citrate (D’Haese and De Broe, 
442 2007). Onset or exacerbation of neurological disorders has been observed during deferoxamine 
443 therapy, presumably because of redistribution of mobilized deferoxamine-bound aluminium into the 
444 brain (Barata et al. 1996). Main symptoms are speech disturbances, tremor, epilepsy and an altered 
445 electroencephalopathic pattern while the serum aluminium concentrations usually exceed 100 µg/L 
446 (Van Ginkel 1991). The disease progresses and ends mostly with the death of the patient within one 
447 year of initial symptoms. Although with the replacement of aluminium-based phosphate binders and 
448 adequate monitoring of dialysis fluids the major clinical manifestations have now disappeared, 
449 aluminium has also been implicated in more subtle diseases, such as microcytic hypochromic anemia, 
450 resistance to erythropoietin treatment and suppression of parathyroid hormone secretion. With regard 
451 to the latter, an increased effect of aluminium has been reported in the presence of a relative iron 
452 deficiency (Smans et al. 2000; Van Landeghem et al. 1997). Comparing different tissues of aluminium-
453 intoxicated uremic patients, however, the relation between aluminium overload and toxicity is not 
454 straightforward. Whilst bone aluminium concentrations in aluminium-related bone disease, are 
455 distinctly elevated, comparable or even higher liver aluminium concentrations are seen without any 
456 apparent toxicity in humans. On the contrary, aluminium toxicity has been demonstrated in the brain at 
457 concentrations below 3 µg/g wet weight. This discrepancy points to the importance of the 
458 ultrastructural/subcellular localization of the element which determines its potential interference with 
459 physiological processes (Verbueken et al. 1984). 
460 Potential exposure routes in water treatment 
461 Lanthanum exposure and toxicity
462 Lanthanum is used as the active component of LMB, consisting of a bentonite carrier which holds the 
463 lanthanum cations within the clay interlayer where they retain their ability to bind with other ions such 
464 as phosphate and thus can be used to remove phosphorus from water bodies and reduce the 
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465 incidence of algal blooms (Robb et al. 2003). Some evidence indicates that ‘free’ (uncomplexed) 
466 lanthanum is toxic to some aquatic organisms (Reitzel et al. 2013a; Herrmann et al. 2016). Free metal 
467 ions are assumed to be responsible for detrimental effects, as in the widely used free ion activity 
468 model (FIAM) (Brown and Markich 2000). Speciation modelling is needed for getting such insight in 
469 complexation and in which species are present, but it might not just be the aqua ion that is mobile or 
470 bioavailable. FIAM predictions are not always confirmed for aluminum (Gensemer and Playle 1999). 
471 Lanthanum is highly reactive, easily giving up the 5d1 and 6s2 electrons and the free ion activity 
472 commonly will be very low in waters suffering from eutrophication, but not in low alkalinity water (see 
473 figure 4 in Spears et al. 2013). The biotic-ligand model assumes complexation of metals with reactive 
474 ligands on/in organisms, for instance by forming surface complexes at a metal transport sites on 
475 membranes (Niogi and Wood 2004). Lanthanum, however, will not easily persist as free La3+ in serum, 
476 in cytoplasm or in natural surface water, which makes us a bit reluctant in referring to FIAM/BLM. We 
477 fully agree that speciation modelling is essential and this is also commonly applied in LMB research 
478 (e.g. Lürling et al. 2017; Lürling et al. 2014; Spears et al., 2013,) and when aluminum is used 
479 (Magelhães et al., 2017).
480 Data from experimental studies where lanthanum was given as lanthanum chloride in drinking water to 
481 rats and mice suggested neurobehavioral impairment, although a clear dose-response relationship is 
482 often lacking (Briner et al. 2000; Damment 2007a; Feng et al. 2006, 2006a; He et al. 2008; Yang et al. 
483 2013; Zarros et al. 2013). Given (i) the maximal amounts at which lanthanum is leached into the water 
484 following application of LMB to surface waters either as filterable lanthanum (nominally <0.2 or 0.45 
485 µm), or total lanthanum or predicted ‘free’ (uncomplexed) ionic lanthanum (0.026 mg/L to 2.30 mg/L; 
486 0.002 mg/L to 0.14 mg/L and <0.0004 mg/L to 0.12 mg/L respectively) (Spears et al. 2013), (ii) the 
487 duration and magnitude of exposure to lanthanum-treated water, (iii) the ability of ‘free’ lanthanum to 
488 directly bind phosphate and other oxyanions in the intestine resulting in a low bioavailability and, (iv) 
489 the absence of significant toxic effects when used therapeutically during years at doses up to 3000 to 
490 5000 times higher than those seen in lanthanum-treated water, one may reasonably accept that 
491 exposure to lanthanum via the drinking water or leisure activities will pose no increased risk for toxicity 
492 in humans even in patients with impaired renal function as biliary excretion is the major route of 
493 elimination of lanthanum. Nevertheless, when using lanthanum treated water to prepare dialysis fluids, 
494 even in dialysis centers equipped with the highest standards of water purification (carbon filtration, 
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495 reverse osmosis, ultrafiltration, deionized water systems, ultraviolet TOC reduction/disinfection), co-
496 measurement of lanthanum during regular monitoring of the in-house treated water and the dialysis 
497 fluid may be indicated as with dialysis treatment the gastrointestinal barrier is circumvented and a 
498 direct transfer of the element towards the blood compartment may occur, in particular for highly protein 
499 bound elements such as lanthanum. 
500 It should be noted that lanthanum-modified bentonite is mostly used to counteract toxic cyanobacterial 
501 blooms, and that such blooms may pose potentially even more severe risks to bathers and definitely to 
502 patients receiving renal dialysis treatment as the ‘Caruaru Syndrome’ unambiguously elucidated with 
503 dozens of casualties (Azevedo et al. 2002; Jochimsen et al. 1998). 
504 Aluminium exposure and toxicity 
505 Varying concentrations of aluminium are present naturally in groundwater and surface water, including 
506 those used as sources of drinking water. The concentration of aluminium in surface water varies, 
507 ranging from 0.012 to 2.25 mg/L in North American rivers (Jones and Bennett, 1984). Furthermore, 
508 aluminium (aluminium sulphate and polyaluminium chloride) has been used for more than three 
509 decades to inactivate phosphate from migrating from lake bed sediments to the overlying waters 
510 (Berkowitz et al. 2006; Cooke et al. 1993a; Lewandowski et al. 2003; Reitzel et al. 2005, 2013; Rydin 
511 and Welch 1998; Rydin et al. 2000; Welch and Cooke 1999; Welch et al., 1988). 
512 Aluminium can liberate from alum due to changes of pH and the presence of low alkalinity water (Aziz 
513 et al. 2007; Paul et al. 2008). Water treatment has been reported to increase the percentage of 
514 dissolved, low molecular weight, chemically reactive and possibly more readily absorbed aluminium 
515 species (La Zerte et al. 1997). The toxicity of aluminium to fish has been well documented, in 
516 particular when the pH decreases to below 6 (Gensemer and Playle 1999). 
517 The hypothesis that aluminium exposure via drinking water is etiologically related to Alzheimer's 
518 disease has led to much debate. The possibility of such a relation was suggested by the presence of 
519 aluminium in senile plaques and neurofibrillary degeneration, two histologic lesions that are 
520 characteristic of the disease (Edwardson et al. 1992). Several studies have found that intake of 
521 aluminium (Praticò et al. 2002; El-Rahman 2003) increases expression of amyloid protein in rodent 
522 tissues, a step that may be critical to the development of Alzheimer's disease. Ecotoxicological studies 
523 have suggested that concentrations of aluminium in drinking water of 0.1 to 0.2 mg/L may increase the 
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524 risk of Alzheimer's disease, with relative risks or odds ratios ranging from 1.35 to 2.67 (Gauthier et al. 
525 1999; Martyn et al. 1989; Rondeau et al. 2000). 
526 With regard to the individual exposure via drinking water, reports have shown a high daily intake of 
527 aluminium (>0.1 mg/day) to be significantly associated with an increased risk of dementia. Conversely, 
528 a concomitant intake of aluminium with an increase of 10 mg/day in silica intake via drinking water was 
529 associated with a reduced risk of dementia (Rondeau et al. 2009). 
530 Until the early 1980s aluminium in the dialysate appeared to be the major source of the metal in 
531 chronic renal failure patients who developed aluminium toxicity (Wills and Savory, 1985). As at that 
532 time adequate water purification systems were not available in all dialysis units, the aluminium 
533 concentration of the dialysate depended primarily on the aluminium concentration of the water with 
534 which it was prepared; whether further enriched with aluminium-contaminated chemicals or not in the 
535 concentrates which are added to the water to prepare the final dialysis fluids (D’Haese et al. 1990). 
536 With the introduction of modern water purification systems in the dialysis centers the incidence of 
537 caricatural aluminium intoxication has now disappeared. Nevertheless, as the concentration gradient 
538 between the dialysate aluminium and the non-protein bound aluminium fraction (<20%) in the serum 
539 compartment is the driving force for aluminium transfer during hemodialysis, chronic accumulation in a 
540 patient with a serum aluminium concentration of e.g. 10 µg/L theoretically may still occur in the 
541 presence of a dialysate aluminium accumulation as low as 3 µg/L. Moreover, accidental intoxications 
542 cannot be excluded (Berend et al. 2004; D’Haese and De Broe 1999a). 
543 In Curaçao, in order to protect a water distribution pipe supplying water to a dialysis center from 
544 corrosion, the pipe was internally lined with a cement mortar. Because of the aggressiveness of the 
545 distilled water, calcium and aluminium leached from the cement mortar into the water used to prepare 
546 dialysate causing a possible hard water syndrome and definite acute aluminium encephalopathy 
547 resulting in the death of 10 patients (Berend et al. 2001). In the South of Portugal, the low rainfall in 
548 the early 1990s resulted in a subsequent decrease in the available water sources resulting in high 
549 concentrations of suspended particles which in turn necessitated the addition of alum as a 
550 flocculating/coagulating agent. The passage of this contaminated water through the water purification 
551 installation of a hemodialysis center resulted in the obstruction of the cartridge filters and malfunction 
552 of the reverse osmosis membranes. Finally insufficiently treated water was sent via dialysis to the 
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553 patients. This led to acute aluminium intoxication, manifested by the epidemic appearance of 
554 encephalopathy, microcytic anemia and death of 18 patients (Barata et al. 1996; Simoes et al. 1994) 
555 Importance of chemical speciation and effects on toxicity
556 Lanthanum 
557 Substantial information exists on the aqueous chemistry and speciation of the REE/lanthanides. 
558 Geochemical modelling with the chemical equilibrium model MINEQL+ indicated that dissolved 
559 lanthanides (Ln) are complexed mainly to carbonates and dissolved organic matter. In the aqueous 
560 phase, the relative abundance of the free ion, LnCO32+, and humic complexes decreases from 
561 lanthanum to lutetium, whereas the relative abundance of Ln(CO3)2+ increases (Moermond et al. 
562 2001). As is the case for any element, the toxicity of lanthanum primarily depends on the inorganic salt 
563 (anion) with which it occurs, with LD50 values for oral doses in rats and mice varying between 2354 
564 and > 10.000 mg/kg body weight for lanthanum chloride (LaCl3) and lanthanum oxide (La2O3) 
565 respectively (Shimomura et al. 1980; Cochran et al. 1980). With regard to the use of LMB, concern 
566 has been raised regarding the potential for release of filterable lanthanum in lakes and surface waters 
567 and the potential unintended ecological implications of this release (Lürling and Tolman 2010; Spears 
568 et al. 2013). The speciation of filterable lanthanum ions is also important when considering the 
569 ecotoxicological impact and of all filterable lanthanum species (i.e. La3+, La(OH)2+, and La(OH)2+). The 
570 La3+ cation carries the greatest risk of biological effects (Das et al. 1988). In humans, once absorbed, 
571 lanthanum circulates >99.7% protein bound in plasma (Damment and Pennick 2007, 2008). High 
572 protein binding, to a certain extent, may explain (i) the low toxicity profile of lanthanum, as it is unlikely 
573 for the lanthanum-protein complex to cross the blood-brain barrier, incorporate in the calcified bone 
574 matrix or interfere with the various ionized calcium-regulated cell biological functions, and (ii) the 
575 almost unique biliary elimination of the element after transferrin-mediated endocytosis by the 
576 hepatocyte (Bervoets et al. 2009).   
577 Aluminium
578 In the environment as well as in the human body aluminium occurs in various chemical species which 
579 have different physical, chemical and biological properties (Harris et al. 1996; Van Landeghem et al. 
580 1998; Yokel and McNamara 2001). The chemical speciation of aluminium in drinking water is of 
581 particular interest, as the form of aluminium regulates its solubility, bioavailability and toxicity. 
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582 Absorption from the gut depends largely on the presence of complexing ligands, particularly carboxylic 
583 acids, with which the metal can form absorbable neutral aluminium species. 
584 One factor determining the form of aluminium in water is pH. In raw water with low concentrations of 
585 dissolved organic compounds such as humic and fulvic acids, the dependence of dissolved aluminium 
586 concentration on pH resembles a parabola with a sharp solubility minimum at around pH 6.5 (Driscoll 
587 and Letterman 1995; Figure 1). The solubility of aluminium increases at lower pH owing to the 
588 formation of Al(OH)2+, Al(OH)2+ and Al(H2O)63+ - often abbreviated as Al3+ and sometimes referred to in 
589 the literature as ‘free’ aluminium. The solid Al(OH)3 is the predominant species between pH 5.2 and 
590 8.8, whereas the soluble Al(OH)4- predominates above pH 9 (Martell and Motekaitis 1989; Figure 1). 
591 The form in which aluminium is present in drinking water is also dependent on whether the water is 
592 fluoridated, as fluoride has a strong affinity for aluminium, particularly under acidic conditions (Nieboer 
593 et al. 1995). When alum is added to raw water for treatment, the form of aluminium changes along a 
594 number of pathways, depending on the quantity of alum added, the temperature, the pH, the types 
595 and concentrations of dissolved materials as well as the types and surface area of particulate matter 
596 present (Driscoll and Letterman 1988). 
597 Concomitant intake of aluminium hydroxide with citrate has been demonstrated to increase 
598 gastrointestinal absorption of the element which was reported to occur in the proximal bowel via the 
599 paracellular pathway due to the ability of citrate to open the epithelial tight junctions (Froment et al. 
600 1989). On the other hand, dissolved silicon has been regarded as an important factor in limiting the 
601 absorption of dietary aluminium (Edwardson et al. 1993; Parry et al. 1998). Once absorbed in the 
602 serum compartment, aluminium strongly binds to proteins mainly transferrin, the remaining 
603 ultrafiltrable fraction to circulate as either bound to phosphate or citrate. Within the serum 
604 compartment it has been demonstrated that aluminium may compete with iron for transferrin binding, 
605 which to a certain extent also determines the tissue deposition and toxicity of aluminium (Van 
606 Landeghem et al. 1997, 1998a; Smans et al. 2000). In contrast to the serum compartment in the brain 
607 aluminium occurs as a non-protein bound, low molecular mass, probably silicate compound. This latter 
608 finding is supported by the high molar ratio of both citrate/transferrin and silica/transferrin in 
609 cerebrospinal fluid. The occurrence of ‘free’ aluminium might also explain the element’s high toxicity at 
610 very low concentrations and gives rise to a hypothesis to explain discrepancies in the neurotoxic 
611 effects of aluminium in dialysis dementia and Alzheimer’s disease (Van Landeghem et al. 1997a).  
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612 Exposure pathways – practical considerations  
613 Application of either lanthanum- or aluminium-containing compounds to natural waters to reduce the 
614 concentration of dissolved phosphorus will result in a range of potential exposure pathways to in-situ 
615 and transient biota and humans over a range of temporal (including acute and chronic exposure) and 
616 spatial scales. We consider the main exposure routes for humans to lanthanum or aluminium in 
617 treated waterbodies to be through drinking treated water, consuming biota (e.g. crustaceans, fish and 
618 plants), dermal exposure via water or sediment and through the inadvertent consumption of sediments 
619 particularly in young children. We describe the likelihood of human health effects associated with 
620 realistic exposure rates below for lanthanum and aluminium. 
621 Water
622 During application of LMB the maximum reported total and filterable lanthanum concentrations in the 
623 surface water of 16 treated lakes were up to 2.3 mg/L and 0.4 mg/L, respectively (Spears et al. 2013). 
624 Smeltzer et al. (1999) reported dissolved aluminium concentrations in Lake Morey (USA) of up to 0.2 
625 mg/L. Reitzel et al. (2013) determined experimentally that dissolved aluminium concentrations may 
626 reach 0.85 mg/L following an application, as a result of diffusion from bed sediments back to the water 
627 column following settlement. Wauer and Teien (2010) reported maximum concentrations of reactive 
628 aluminium of 2.0 mg/L in field observations. Given that lanthanum as lanthanum carbonate when used 
629 therapeutically (Fosrenol®, Shire Pharmaceuticals) is administered at doses up to 1500 mg per day 
630 (900 mg lanthanum/day) without toxicity to the patients after up to 10 years of treatment (Hutchison 
631 et al. 2016), consumers would have to consume at least 390 L of the surface water per day to attain a 
632 similar, nominally safe dose. Using the highest application dose of 333 mg/L LMB (Spears et al. 2013) 
633 a consumption of 54 L is needed to attain a dose of 900 mg lanthanum.  It is likely that in the absence 
634 of episodic resuspension, the highest risk of exposure will occur within the following few days to 
635 weeks. 
636 Sediment
637 Following settling of the applied phosphorus removal agent, the bed sediments are the location of 
638 treated waterbodies where lanthanum concentrations are highest following an application. 
639 Consumption of these sediments, although unlikely, may be considered, for example, playing children 
640 may express some geophagia, whereas pica disorder may result in considerable consumption of soil 
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641 material (Rose et al., 2000). Soil pica is referred to as eating 500 mg to more than 50 g of soil per day 
642 (Callahan, 2003). Using the data presented in Table 2 in Spears et al. (2013) an average dose of 348 
643 g LMB/m2 (range 6-667) is derived. With an assumed maximum 5% weight of lanthanum in LMB this 
644 makes an average of 17.4 g lanthanum/m2 (range 0.3-33.3) or 1.74 mg lanthanum/cm2. Using the data 
645 presented by Reitzel et al. (2013) applied aluminium concentrations in bed sediments may reach 54 g 
646 aluminium/m2, although Wauer and Teien (2010) report sediment aluminium concentrations of up to 
647 200 g aluminium/m2.  Assuming a specific density of 1 g/cm3 and a thickness of 1 cm, a person would 
648 need to consume 860 g of sediment to reach a nominally safe dose of 1500 mg lanthanum, or 450 g 
649 using the highest lanthanum application dosing (3.33 mg lanthanum/cm2). 
650 Based on the Tolerable Weekly Intake (TWI) of 1 mg aluminium per kg body-weight as proposed by 
651 the European Food and Safety Authority (2008), a 60 kg person would need to eat 3 to 11 g of 
652 sediment following sediment aluminium content of Reitzel et al (2013a) and Wauer and Teien (2010), 
653 respectively, to reach this TWI.
654 Crustaceans
655 Accumulation of lanthanum in the crustacean zooplankton Daphnia magna has been observed (Yang 
656 et al., 1999), yet these small animals are not directly consumed by humans. Nonetheless, they may 
657 provide a food chain vector of transmission via fish that may predate heavily on zooplankton. The most 
658 obvious human exposure route is via bottom dwelling crustaceans, such as crayfish that may be 
659 exposed for prolonged periods to relatively high concentrations of LMB. In Lake Rauwbraken (The 
660 Netherlands) the lanthanum concentration in the flesh of crayfish (Orconectes limosus) increased from 
661 0.12  0.05 g lanthanum/g dry-weight before application to 89  42 g lanthanum/g dry weight in 
662 animals caught 4months after application and 37  13 g lanthanum/g dry weight in animals collected 
663 14 months after treatment. In practical terms, this means that a person would have to consume daily 
664 10 kg of crayfish with 89 g lanthanum/g and 24 kg of crayfish with 37 g lanthanum/g to reach the 
665 recommended therapeutic prescription dose of lanthanum carbonate. In a controlled laboratory 
666 experiment, exposure of marbled crayfish (Procambarus fallax f. virginalis) to 67 g LMB/m2 led to a 
667 maximum lanthanum concentration in the flesh of 13.6 g lanthanum/g dry weight (Van Oosterhout et 
668 al. 2014). Consequently, a daily consumption of 66 kg crayfish would equal the safe recommend 
669 therapeutic dose of Fosrenol®. It should be noted that the lanthanum concentration is expressed per 
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670 unit dry-weight that only constitutes approximately 17% of the live-weight and thus daily crayfish 
671 consumption would need to be almost 390 kg to attain the nominally safe adult medication dose. 
672 Data on aluminium concentrations in crustacea are sparse in relation to whole lake applications. 
673 However, Elangovan et al. (1999) reported uptake of aluminium into in the aquatic isopod Asellus 
674 aquaticus to reach about 2.4 mg aluminium/g dry weight and that aluminium uptake into tissue of the 
675 animal can be explained through a significant linear regression relationship with the aluminium 
676 concentration in the water column. 
677 Fish
678 Data on La concentrations in edible fish parts after LMB applications are rare. Some lanthanum 
679 accumulation in the liver and hepatopancreas of fish collected from Lake Okareka (New Zealand) has 
680 been reported, while lanthanum in the flesh of trout and koura remained below the level of detection 
681 (Landman et al., 2007). Lanthanum concentrations in the livers of eel caught two years after a whole 
682 lake treatment showed a 94 fold increase compared to pre-intervention liver concentrations and a 133 
683 fold increase in eels caught five years later (Waajen et al., 2017). Elevated lanthanum concentrations 
684 were also found  in the flesh of fish collected before and after a whole lake application in Lake De Kuil, 
685 The Netherlands (Waajen et al., 2016), and from LMB treated and control compartments constructed 
686 in urban ponds (Waajen et al., 2016a; Waajen et al., 2017).. In Lake De Kuil, prior to application, the 
687 mean lanthanum concentration in the flesh of the five most abundant fish species (bream, eel, perch, 
688 pike, tench) was 0.03  0.02 g lanthanum/g dry weight (Waajen et al., 2017). Two years after the 
689 LMB application at a dose of 593 g LMB/m2 Waajen et al., 2016), the lanthanum concentration in the 
690 muscle tissue of these five species had increased to an average of 0.10  0.05 g lanthanum/g dry 
691 weight and after 5 years the lanthanum had returned to pre-application concentrations (0.03  0.01 g 
692 lanthanum/g dry weight) in specimens of these five fish species. In two urban ponds in The 
693 Netherlands 300 m2 (pond Dongen) and 400 m2 sized compartments (pond Eindhoven) were 
694 constructed of which some were treated with 750 g LMB/m2 and 1130 g LMB/m2, respectively (Waajen 
695 et al., 2016a). The muscle tissue of fish collected after two years in the LMB treated compartments in 
696 pond Dongen contained on average 0.22  0.34 g lanthanum/g dry weight, while that of non-LMB 
697 exposed fish was on average 0.06  0.09 g lanthanum/g dry weight. In pond Eindhoven, muscle 
698 tissue in LMB exposed fish was 0.07  0.06 g lanthanum/g dry weight, while that of non-LMB 
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699 exposed fish was 0.03  0.02 g lanthanum/g dry weight. Although lanthanum from LMB thus may 
700 accumulate in fish and raised lanthanum concentrations have been reported up to five years following 
701 treatment with the highest lanthanum concentration found in liver, no toxic effects were observed 
702 following LMB bentonite treatments (Waajen et al., 2017). 
703 Taking the highest flesh lanthanum concentrations measured of all examined fish (0.81 g 
704 lanthanum/g dry weight) a person would have to consume more than 1000 kg of fish per day to reach 
705 the nominally safe recommended therapeutic dose of lanthanum in adults. 
706 Wauer and Teien (2010) reported concentrations of aluminium in the gills of perch (Perca fluviatilis) 
707 and ruffe (Gymnocephalus cemuus) up to about 100 µg aluminium/g dry weight and 401 µg 
708 aluminium/g dry weight respectively, although no similar observations were reported for roach (Rutilus 
709 rutilus), bream (Abramis brama),  or silver carp (Hypophthalmichthys molitrix). Given the >100-fold 
710 higher aluminium concentrations in combination with a 10-100 higher gastrointestinal absorption as 
711 compared to lanthanum (see above) potential aluminium toxicity should be considered. In this context 
712 it is worth to be mentioned that given the fact that aluminium is eliminated via the kidney, the risk for 
713 toxic effects, even with this degree of exposure is rather limited in subjects with normal renal function. 
714 Nevertheless regular monitoring of aluminium in the drinking water and consumable fish by water and 
715 health authorities should be performed. In individuals with impaired renal function regularly consuming 
716 local fish or water, serum aluminium measurement is recommended, particularly in patients presenting 
717 with undefined bone and/or neurologic complaints or signs of anemia. Here the first line of therapy 
718 should consist in the withdrawal of these sources of aluminium exposure. 
719  
720 Plants
721 Aquatic plants may take up lanthanum and a lanthanum bioaccumulation factor of 138 for duckweed 
722 has been reported (Yang et al., 1999). The aquatic macrophyte Elodea nuttallii was harvested on 
723 three occasions from the different compartments in the above-mentioned urban waters (Waajen et al., 
724 2016a). Samples consisting of the complete plants including the roots and shoots were analysed for 
725 lanthanum (Waajen et al., 2017). The mean La concentration of E. nuttallii from control compartments 
726 varied between 0.35 and 7.03 μg lanthanum/g dry weight at pond Dongen and between 0.14 and 
727 13.53 μg lanthanum/g dry weight at pond Eindhoven, the stocking plant material at the start of the 
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728 experiment contained on average 7.50 μg lanthanum/g dry weight. The mean lanthanum 
729 concentration of E. nuttallii from the LMB treated compartments reached up to 380 μg lanthanum/g at 
730 pond Dongen and 871 μg lanthanum/g at pond Eindhoven. Although consumption of macrophytes by 
731 humans is restricted to a few species (e.g., lotus, water chestnut, water caltrop, water spinach, 
732 watercress) and E. nuttallii is normally not one of the consumed aquatic plants, a person still would 
733 need to ingest 2.4 kg per day of dry plant equivalent from Dongen and 1 kg of dried plant equivalent 
734 per day from pond Eindhoven to attain the nominally safe lanthanum dose recommended for 
735 therapeutic purposes. Use of harvested LMB exposed plant material in fish feed (Hasan and 
736 Chakrabarti, 2009) or cattle fodder (Banerjee and Matai, 1990; Goopy and Murray, 2003), however, 
737 warrants caution as no information on the magnitude of possible La transfer and bioaccumulation 
738 exists.
739 Data on macrophyte uptake of aluminium following a whole lake treatment do not appear to be 
740 available in the peer reviewed literature. However, we draw here on data published by Goulet et al 
741 (2005) on a series of phytoremediation mesocosm experiments (at water concentrations of up to 1 mg 
742 total dissolved aluminium/L) in which aluminium uptake across 4 different macrophyte species (i.e. 
743 Potamogeton epihydrus, Nuphar variegatum, Lemna minor and Typha latifolia) ranged between < 0.01 
744 and 17.2 mg aluminium/g dry weight for root tissues; 0.34 and 1.44 mg aluminium/g dry weight for 
745 stem tissues and 0.18 and 6.25 mg aluminium/g dry weight for leaf tissues. 
746 General conclusions
747  Because of their inherently strong phosphate binding capacity over a wide range, and mostly 
748 overlapping set of physico-chemical conditions, application of aluminium- and lanthanum-
749 based compounds has proven to be efficacious for water treatment and therapeutic phosphate 
750 control in uremic patients.
751  Kinetics as well as mechanisms underlying the possible toxic effects of aluminium and 
752 lanthanum substantially differ from each other  
753  Although aluminium and lanthanum have physicochemical similarities their aqueous chemistry 
754 differs with hydrolysis of lanthanum occurring at substantially higher pH than that of aluminium 
755  The speciation, concentration and exposure pathways to living organisms of lanthanum and 
756 aluminium is strongly dependent on pH and salinity
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757  The extent of lanthanum leached into LMB-treated water reported so far, do not exceed 
758 concentrations that might be considered harmful, however, considerable care in manufacture 
759 and quality control needs to be exercised to minimize risk to receiving aquatic environments. 
760  Regular monitoring of both aluminium and lanthanum concentrations in lanthanum-
761 /aluminium-treated water by the responsible authorities is recommended to avoid accidental 
762 acute or chronic lower level exposure
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0.4 mg FLa/L < 12 months Spears et al., 2013 Low Mod-High Low
0.2 mg FAl/L >30 days Scmeltzer et al., 1999 Low Mod-High Low
Bed sediments
33.3 g La/m2 Unknown Spears et al., 2013 Low Mod-High Low
200 g Al/m2 Unknown Wauer and Teien, 2010 Low Mod-High Low
Crustacea
Orconectes limosus 131 µg La/g DW >14 months Low Mod-High Low
Asellus aquaticus 2400 µg Al/g DW < 1 month Elangovan et al., 1999 Low Mod-High Low
Fish 
Perca fluviatilis 0.56 µg La/g DW 5 years Waajen et al., 2017 Low Mod-High Low
Gymnocephalus cemuus 401 µg Al/g DW Unknown Wauer and Teien, 2010 Low Mod-High Low
Plants
Elodea nuttallii 871 µg La/g DW Unknown Waajen et al., 2017 Low Mod-High Low
Lemna minor 17 mg Al/g DW Unknown Goulet et al., 2005 Low Mod-High Low
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773 Table 1. Maximum reported concentrations for lanthanum (La) and aluminium (Al) in various abiotic and biotic components of lakes following additions 
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1169 Legend to Figure
1170
1171 Effect of pH on the aqueous chemistry of lanthanum and aluminium. The speciation of lanthanum and 
1172 aluminium was evaluated by chemical equilibrium modelling using the program CHEAQS Pro (release 
1173 P2013.1; Verweij, 2013) in the pH range 1 – 14 with 1 μM La or Al and 1 mM NaCl. The five most 
1174 prominent species are presented.
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Figure 1. Lanthanum and aluminium speciation as a function of pH in the systems La-H2O and Al-H2O. 
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Highlights
 Geo-engineering materials containing La and Al used to manage P in lakes
 Potential impact of the use of these compounds on human health is of interest
 La and Al uptake, kinetics and toxicity profile differ within the humans and organisms
 Monitoring of La and Al is recommended to avoid acute and chronic exposure.
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